Ängelholm, March 4th, 2025
“Ever since the introduction of clozapine to the care and treatment of patients with therapy-resistant schizophrenia (TRS), there has been a need for patient- friendly, reliable, and point-of-care blood monitoring method.
HemoCue has, in line with this, performed studies to evaluate whether the HemoCue® WBC DIFF System could be used in this clinical area, including an interference study and a clinical risk assessment.”
“HemoCue has concluded that the use of the system is suitable for monitoring of total white blood cell count (WBC) and absolute neutrophil count (ANC) in patients treated with clozapine. With this evaluation of the use, the HemoCue® WBC DIFF system can be marketed to psychiatric care within the current labelling.”
Francois Dupont
Director Global Product Management Marketing